कंपनी लोड हो रही है
Just reported
Q3 2026 results
From Generate Biomedicines's results release of 12 नवंबर 2026; its quarterly report has since been filed.
Revenue
Actual
$4.2M
-56% y/y
-33% q/qGuided
—
No guide given
EPS, GAAP
Actual
-$0.68
Guided
—
No guide given
Operating income, GAAP
Actual
-$91.5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 अक्टू॰ 2026CAGraded C, now A
कमाई कैसे होती है
- Research collaboration payments100%
आमदनी के हिस्से six months ended June 30, 2026 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
क्या बेचती है3
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
कौन खरीदता है2
- Amgen, which pays for research under a collaboration agreement.
- Novartis, which pays for research under a collaboration agreement.
किस पर टिका है, और क्या इसे तोड़ सकता है
कारोबार किन चीज़ों पर टिका है
- 1Current revenue depends on research work under agreements with Amgen and Novartis; the company says the work under both agreements is nearing completion.
- 2Clinical research and manufacturing rely in part on outside providers, including contract research organizations and contract development and manufacturing organizations.
- 3Developing and selling medicines depends on clinical trials and regulatory approval.
क्या ग़लत हो सकता है
- 1GB-0895 and the other experimental medicines may not prove safe and effective in clinical trials or receive regulatory approval.
- 2The company has no medicine sales, and its current collaboration revenue depends on research agreements whose work is nearing completion.
- 3The company has ongoing operating losses and expects to need additional funding to continue research and clinical development; it may not obtain that funding on acceptable terms or at all.
Generate Biomedicines, Inc. के बारे में
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
- मुख्यालय
- Cambridge, Massachusetts
- स्थापना
- 2018
- सूचीबद्ध
- NASDAQ
- वित्त वर्ष का अंत
- December 31
Generate Biomedicines, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
